Biotricity, Inc. (BTCY)
USD 0.5
(2.04%)
USD 0.5
(2.04%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 | 17.18 Million USD | -17.59% |
| 2023 | 20.85 Million USD | -2.14% |
| 2022 | 21.3 Million USD | 45.69% |
| 2021 | 14.62 Million USD | 28.1% |
| 2020 | 11.41 Million USD | 31.95% |
| 2019 | 8.65 Million USD | 12.02% |
| 2018 | 7.72 Million USD | 29.98% |
| 2017 | 5.94 Million USD | 15.83% |
| 2016 | 5.13 Million USD | 5625.58% |
| 2015 | 89.59 Thousand USD | -0.36% |
| 2014 | 89.92 Thousand USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 FY | 17.18 Million USD | -17.59% |
| 2024 Q1 | 4.23 Million USD | 11.9% |
| 2024 Q3 | 3.44 Million USD | -17.57% |
| 2024 Q4 | 5.31 Million USD | 54.12% |
| 2024 Q2 | 4.18 Million USD | -1.14% |
| 2023 Q3 | 5.65 Million USD | 6.49% |
| 2023 Q2 | 5.3 Million USD | -0.09% |
| 2023 FY | 20.85 Million USD | -2.14% |
| 2023 Q1 | 5.31 Million USD | -18.93% |
| 2023 Q4 | 3.78 Million USD | -33.09% |
| 2022 Q4 | 6.55 Million USD | 17.88% |
| 2022 Q3 | 5.56 Million USD | -11.79% |
| 2022 Q2 | 6.3 Million USD | 51.07% |
| 2022 Q1 | 4.17 Million USD | 13.31% |
| 2022 FY | 21.3 Million USD | 45.69% |
| 2021 Q1 | 3.61 Million USD | -18.69% |
| 2021 FY | 14.62 Million USD | 28.1% |
| 2021 Q2 | 2.99 Million USD | -17.27% |
| 2021 Q3 | 4.01 Million USD | 34.25% |
| 2021 Q4 | 3.68 Million USD | -8.39% |
| 2020 Q2 | 2.23 Million USD | -1.16% |
| 2020 Q3 | 2.62 Million USD | 17.31% |
| 2020 FY | 11.41 Million USD | 31.95% |
| 2020 Q1 | 2.26 Million USD | 23.39% |
| 2020 Q4 | 4.45 Million USD | 69.41% |
| 2019 Q1 | 2.43 Million USD | -12.66% |
| 2019 FY | 8.65 Million USD | 12.02% |
| 2019 Q3 | 2.26 Million USD | 2.17% |
| 2019 Q2 | 2.21 Million USD | -9.18% |
| 2019 Q4 | 1.83 Million USD | -18.83% |
| 2018 Q1 | 1.38 Million USD | -10.64% |
| 2018 Q2 | 1.45 Million USD | 5.29% |
| 2018 Q3 | 2.09 Million USD | 44.04% |
| 2018 Q4 | 2.79 Million USD | 33.21% |
| 2018 FY | 7.72 Million USD | 29.98% |
| 2017 Q1 | 800.8 Thousand USD | 38.88% |
| 2017 Q4 | 1.54 Million USD | -29.46% |
| 2017 FY | 5.94 Million USD | 15.83% |
| 2017 Q3 | 2.19 Million USD | 56.24% |
| 2017 Q2 | 1.4 Million USD | 75.21% |
| 2016 Q2 | 1.22 Million USD | 149.3% |
| 2016 FY | 5.13 Million USD | 5625.58% |
| 2016 Q4 | 576.62 Thousand USD | -59.86% |
| 2016 Q3 | 1.43 Million USD | 17.11% |
| 2016 Q1 | 492.01 Thousand USD | 0.0% |
| 2015 Q1 | 27.64 Thousand USD | 0.0% |
| 2015 Q2 | 20.58 Thousand USD | -25.52% |
| 2015 Q3 | 18.9 Thousand USD | -8.18% |
| 2015 FY | 89.59 Thousand USD | -0.36% |
| 2014 FY | 89.92 Thousand USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Acutus Medical, Inc. | 11.22 Million USD | -53.105% |
| Cell MedX Corp. | 313.43 Thousand USD | -5382.739% |
| Dynatronics Corporation | 9.9 Million USD | -73.441% |
| Nemaura Medical Inc. | 7.13 Million USD | -140.72% |
| PetVivo Holdings, Inc. | 11.36 Million USD | -51.261% |
| RetinalGenix Technologies Inc. | 2.08 Million USD | -723.39% |
| Sonendo, Inc. | 68.46 Million USD | 74.9% |
| Telesis Bio, Inc. | 63.48 Million USD | 72.933% |
| Talis Biomedical Corporation | 67.18 Million USD | 74.422% |
| Viveve Medical, Inc. | 22.17 Million USD | 22.498% |